ESC 365 - The real-world effectiveness and safety of edoxaban treatment in 27,333 Global ETNA-AF programme patients with and without a history of heart failure

ESC Professional Premium Access

The real-world effectiveness and safety of edoxaban treatment in 27,333 Global ETNA-AF programme patients with and without a history of heart failure

Session: Anticoagulant therapy: real world use and clinical challenges

Topic: Anticoagulants

Speaker: Associate Professor J. Siller-Matula (Vienna, AT)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Associate Professor Jolanta Siller-Matula

Medical University of Vienna, Vienna (Austria)

9 presentations

0 follower

4 more presentations in this session

Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study

Speaker: Mr M. Grymonprez (Gent, BE)

Oral anticoagulation in patients with atrial fibrillation and stage IV and V chronic kidney disease: a systematic review and meta-analysis

Speaker: Doctor A. Miranda-Arboleda (Boston, US)

Potentially inappropriate prescribing and its demographic and clinical correlates in older adults with atrial fibrillation: a population-based study

Speaker: Ms C. Amrouch (Ghent, BE)

The effect of eplerenone on the disease onset and progression of phospholamban cardiomyopathy in presymptomatic mutation carriers: results of the i-PHORECAST trial

Speaker: Mr R. De Brouwer (Groningen, NL)

Access the full session

Anticoagulant therapy: real world use and clinical challenges

Speakers: Associate Professor J. Siller-Matula, Mr M. Grymonprez, Doctor A. Miranda-Arboleda, Ms C. Amrouch, Mr R. De Brouwer

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources